Could NovoCure Limited (NVCR) Skyrocket Even More? The Stock Just Made All Time High

The stock of NovoCure Limited (NASDAQ:NVCR) reached all time high today, Aug, 15 and still has $95.01 target or 5.00 % above today’s $90.49 share price. This indicates more upside for the $8.88B company. This technical setup was reported by Barchart.com. If the $95.01 PT is reached, the company will be worth $444.20 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 4.77% or $4.12 during the last trading session, reaching $90.49. About 757,016 shares traded. NovoCure Limited (NASDAQ:NVCR) has risen 149.16% since August 15, 2018 and is uptrending. It has outperformed by 149.16% the S&P500.

Analysts await NovoCure Limited (NASDAQ:NVCR) to report earnings on October, 24. They expect $-0.02 EPS, up 84.62 % or $0.11 from last year’s $-0.13 per share. After $-0.01 actual EPS reported by NovoCure Limited for the previous quarter, Wall Street now forecasts 100.00 % negative EPS growth.

NovoCure Limited (NASDAQ:NVCR) Ratings Coverage

Among 3 analysts covering NovoCure (NASDAQ:NVCR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. NovoCure has $9100 highest and $50 lowest target. $73.75’s average target is -18.50% below currents $90.49 stock price. NovoCure had 9 analyst reports since March 20, 2019 according to SRatingsIntel. The stock of NovoCure Limited (NASDAQ:NVCR) earned “Neutral” rating by JP Morgan on Friday, July 26. The firm has “Buy” rating given on Friday, July 26 by Mizuho.

More notable recent NovoCure Limited (NASDAQ:NVCR) news were published by: Benzinga.com which released: “Stocks That Hit 52-Week Highs On Wednesday – Benzinga” on August 14, 2019, also Seekingalpha.com with their article: “NovoCure: Updates To Thesis And 2019 Outlook – Seeking Alpha” published on December 19, 2018, Businesswire.com published: “CMS Establishes 2019 Monthly Fee Schedule Amount for Optune® – Business Wire” on July 18, 2019. More interesting news about NovoCure Limited (NASDAQ:NVCR) were released by: Nasdaq.com and their article: “Notable ETF Inflow Detected – IWM, HAE, NVCR, CHGG – Nasdaq” published on July 24, 2019 as well as Fool.com‘s news article titled: “5 Key Takeaways From NovoCure’s Big First Quarter – Motley Fool” with publication date: May 07, 2019.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $8.88 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

NovoCure Limited (NASDAQ:NVCR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.